Skip to main content
Premium Trial:

Request an Annual Quote

Mega Fight for Metadata Market

Premium

Could InforMax’s recent alliance with Biomax Informatics be the missing piece it has needed to go head-to-head with its primary competitor, Lion Bioscience? The deal gives InforMax distribution and co-marketing rights to the BioRS Integration and Retrieval System.

Steve Lincoln, senior vice president of life science informatics at InforMax, says that Martins- reid, Germany-based Biomax has positioned the BioRS technology to compete with Lion’s SRS platform. But Christian Marcazzo, Lion’s director of product marketing, isn’t worried. “I’m looking forward to the competition,” Marcazzo says. “It’s going to be fun.”

BioRS integrates heterogeneous public and proprietary databases. The new capability will support a “holistic system” that Lincoln says will set InforMax apart from competitors.

Marcazzo sees the adoption of BioRS as “validation of Lion’s metadata approach to data integration,” and claims that Lion is still one step ahead. “While Biomax and InforMax work together to try and catch up with us,” he says, “we’re actively working to start expanding the applicability of SRS into other domains.”

Through hitching its wagon to Informax, Biomax can gain access to Informax’s customer base of over 500 organizations throughout Europe, 150 of which are in Germany.

Lincoln acknowledges that the InforMax/Biomax partnership looks like an aggressive push onto Lion’s home turf, but says, “I don’t think this particular deal makes [the competition with Lion] any better or worse. This deal for us is part of our strategy of diversifying our product line.”

—Bernadette Toner

 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.